Physician Assistant Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Catherine Walgren

Physician Assistant, Medical Bozeman, MT Physician Assistant

NPI 1689770323 CMS profile 10475404

931 Highland Blvd Ste 3130, Bozeman, MT 59715

Open in the dashboard

General payments

$1,815

86 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Catherine Walgren of Bozeman, MT is reported in the CMS Open Payments database as having received $1,815 across 86 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 74th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $401 13
2024 General $671 32
2023 General $686 37
2022 General $56 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Catherine Walgren
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Catherine Walgren were reported at $401. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Catherine Walgren Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $0 $156 $41–$563 $132
2022 $56 $185 $55–$649 $149
2023 $686 $199 $58–$717 $160
2024 $671 $206 $62–$740 $164
2025 $401 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Janssen Biotech, Inc. $356 14 payments
  2. AstraZeneca Pharmaceuticals LP $205 6 payments
  3. Celgene Corporation $181 11 payments
  4. Lilly USA, LLC $113 6 payments
  5. Merck Sharp & Dohme Corporation $108 5 payments
  6. Pharmacyclics LLC, An AbbVie Company $106 6 payments
  7. Regeneron Healthcare Solutions, Inc. $79 3 payments
  8. Seattle Genetics, Inc. $75 4 payments
  9. Pfizer Inc. $69 4 payments
  10. Stemline Therapeutics Inc. $59 2 payments
  11. Other $464 25 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $1,672 84 payments
  2. Education $143 2 payments
Products named General payments · program years 2022–2025
  1. TECVAYLI $212 6 payments
  2. TALVEY $178 5 payments
  3. DARZALEX $172 4 payments
  4. REBLOZYL $149 9 payments
  5. VERZENIO $113 6 payments
  6. KEYTRUDA $108 5 payments
  7. IMBRUVICA $91 5 payments
  8. LIBTAYO $79 3 payments
  9. RETEVMO $76 4 payments
  10. JAYPIRCA $76 4 payments
  11. Other $1,260 65 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

369

Median for Physician Assistant: 241

Drug cost

$4,596

Median for Physician Assistant: $4,110

Branded share of claims

15.4%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Anastrozole Generic 29 $701
Triamcinolone Acetonide Generic 16 $633
Dexamethasone Generic 37 $473
Prochlorperazine Maleate Generic 27 $366
Diphenoxylate-Atropine Diphenoxylate Hcl/Atropine Brand 13 $341
Letrozole Generic 16 $308
Potassium Chloride Generic 19 $265
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 15 $246
Acyclovir Generic 25 $230
Ondansetron Odt Ondansetron Brand 15 $225

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$43,825

Medicare's payments for the services billed

Medicare patients

232

Average age 74

Services billed

898

112 women, 120 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 59%
Cancer 51%
Arthritis 41%
Depression 24%
Ischemic heart disease 23%
Diabetes 18%
Chronic kidney disease 18%
Osteoporosis 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 34 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
IMFINZI
  • AstraZeneca Pharmaceuticals LP $52
$52 — —
REBLOZYL
  • Celgene Corporation $50
$50 — —
LIBTAYO
  • Regeneron Healthcare Solutions, Inc. $44
$44 — —
TIBSOVO
  • Servier Pharmaceuticals LLC $43
$43 — —
Orserdu
  • Stemline Therapeutics Inc. $33
$33 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 34 with Patron

Records

86 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Montana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record